Related Experiment Video
Updated: May 28, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[New treatments for hepatitis C, which targets, what timeline?]
Nicolas Goossens1, Francesco Negro
1Service de gastroentérologie et d'hépatologie, Département des spécialités, HUG, 1211 Genève 14. nicolas.goossens@hcuge.ch
Abstract:
The hepatitis C virus (HCV) is a global major health burden, its response to current treatment is unfortunately inadequate, in particular for genotype 1. Two new direct acting antivirals, that inhibit NS3/4A viral protease, will soon be available on the Swiss market: telaprevir and boceprevir. These substances increase the rate of sustained viral response, in HCV genotype 1 infected patients, when coadministered with pegylated interferon and ribavirin. However, these new molecules may lead to serious adverse effects and drug interactions with which the specialist and the primary care physician must be familiar.
Related Concept Videos
Hepatitis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

